Clinical trials: Thyroid Gland Medullary Carcinoma
Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma
Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors
This phase I/II trial studies how well tiragolumab and atezolizumab works when given to children and adults with SMARCB1 or SMARCA4 deficient tumors that have either come back (relapsed) or do not respond to therapy (refractory).
- Conditions
- Atypical Teratoid/Rhabdoid Tumor, Epithelioid Sarcoma, Kidney Medullary Carcinoma, Malignant Solid Neoplasm
- Trial name
- NCT05286801
- Testing
- Atezolizumab, Biospecimen Collection, Computed Tomography
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 86 people
- Sponsor
- National Cancer Institute (NCI)
Thyroid Cancer
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
- Trial name
- NCT00098345
- Testing
- ZD6474 (vandetanib)
- Where
- 6 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Medullary Thyroid Cancer
Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib
Study in healthy volunteers to assess effect of omeprazole and ranitidine on the pharmacokinetics of vandetanib
- Trial name
- Vandetanib (NCT01539655)
- Testing
- vandetanib, omeprazole, ranitidine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Sanofi
Medullary Thyroid Cancer (MTC)
QUILT-3.006 for Recurrent Medullary Thyroid Cancer
Background: GI-6207 is an experimental cancer vaccine made with baker's yeast. The yeast has been modified to help the immune system target a protein called CEA.
- Trial name
- NCT01856920
- Testing
- GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- NantCell, Inc.
Locally Advanced or Metastatic Medullary Thyroid Cancer, Medullary Thyroid Cancer
Study to Determine if Contacting Patients With MTC More Frequently Results in Earlier Detection and Treatment of Signs and Symptoms of AEs and Thus a Decrease in the Percentage of Time Patients Experience AEs During First 12 Months on Vandetanib Treatment
The purpose of this study is to evaluate the effect of patient outreach program on the proportion of time patients with MTC experience moderate or severe AEs during first 12 months of treatment with vandetanib
- Trial name
- NCT01298323
- Testing
- Patient outreach, Vandetanib
- Where
- 66 sites in Australia, Austria and 18 more
- Volunteers
- 205 people
- Sponsor
- Sanofi
Medullary Thyroid Carcinoma, Hyperparathyroidism
PET-TC in Thyroid Evaluation
The thyroid gland may have a diffuse or focal uptake of numerous PET/CT radiopharmaceuticals and this may be correlated with underlying benign and malignant thyroid/parathyroid pathologies.
- Conditions
- Medullary Thyroid Carcinoma, Hyperparathyroidism, Parathyroid Carcinoma
- Trial name
- PEPATI-MN-2024 (NCT06852144)
- Testing
- clinical practice drug treatment
- Where
- Italy
- Volunteers
- 418 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma
Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma
This trial tests how well giving enfortumab vedotin works for the treatment of differentiated thyroid cancer that does not respond to treatment with radioiodine (refractory), anaplastic thyroid cancer, medullary thyroid cancer or…
- Conditions
- Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic NUT Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma
- Trial name
- NCT07863765
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Northwestern University
Medullary Thyroid Cancer (MTC)
A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations
This trial is a prospective, observational Phase II clinical study. For patients with locally advanced and/or metastatic medullary thyroid carcinoma with RET gene mutations who require systemic treatment, they are randomly…
- Trial name
- NCT07048964
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of TY-1091 in Patients With Advanced Solid Tumors
This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of TY-1091 administered orally in…
- Conditions
- RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer, RET-altered Papillary Thyroid Cancer, Neoplasms
- Trial name
- NCT05675605
- Testing
- TY-1091
- Where
- China
- Volunteers
- 248 people
- Sponsor
- TYK Medicines, Inc
Medullary Thyroid Cancer
A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer
The reason for this study is to see if the study drug selpercatinib is safe and more effective compared to a standard treatment in participants with rearranged during transfection (RET)-mutant medullary thyroid cancer (MTC) that…
- Trial name
- LIBRETTO-531 (NCT04211337)
- Testing
- Selpercatinib, Cabozantinib, Vandetanib
- Where
- 143 sites in United States, Australia and 18 more
- Volunteers
- 291 people
- Sponsor
- Loxo Oncology, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
This is a global, multicenter, open-label pre-approval access program to provide access to pralsetinib (BLU-667) until such time that pralsetinib becomes available through other mechanisms or the Sponsor chooses to discontinue…
- Trial name
- NCT04204928
- Testing
- pralsetinib (BLU-667)
- Sponsor
- Blueprint Medicines Corporation
Solid Tumor, Thyroid Cancer
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Objectives: Primary objectives: To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors.
- Trial name
- NCT00354523
- Testing
- Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Thyroid Cancer, Medullary
177Lu-PP-F11N in Combination With Sacubitril for Receptor Targeted Therapy and Imaging of Metastatic Thyroid Cancer
The purpose of this study is to determine the use of 177Lu-PP-F11N for imaging and therapy of patients with advanced medullary thyroid carcinoma (MTC). 177Lu-PP-F11N is a gastrin analogon, binding to cholecystokinin-2 receptors.
- Trial name
- NCT03647657
- Testing
- 177Lu-PP-F11N, Sacuitril
- Where
- Switzerland
- Volunteers
- 8 people
- Sponsor
- University Hospital, Basel, Switzerland
Head and Neck Cancer
Iodine I 131 in Treating Patients With Thyroid Cancer
RATIONALE: Radioactive iodine kills thyroid cancer cells by giving off radiation. PURPOSE: This clinical trial is studying the side effects, best dose, and how well iodine I 131 works in treating patients with thyroid cancer.
- Trial name
- NCT00416949
- Testing
- Patient-specific dosimetry
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Thyroid Cancer
Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
The purpose of this study is to determine the effectiveness of two anticancer drugs, everolimus and pasireotide, in patients with thyroid cancer when the cancer is no longer responding to treatment with radioiodine or where it is…
- Trial name
- NCT01270321
- Testing
- Everolimus, Pasireotide, Everolimus and Pasireotide
- Where
- 3 sites in United States
- Volunteers
- 42 people
- Sponsor
- Emory University
Medullary Thyroid Cancer
Vandetanib Risk Minimisation Effectiveness
Effectiveness of risk minimisation interventions for vandetanib in Canada
- Trial name
- NCT01757470
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Genzyme, a Sanofi Company
Medullary Thyroid Carcinoma, Nodular Goiter
Calcitonin in Needle Wash Using Electrochemiluminescence Method For Diagnosis Of Medullary Thyroid Carcinoma.
Medullary thyroid carcinoma (MTC) is a tumor originating from parafollicular C cells of the thyroid. (1) Representing 1 to 7% of all thyroid carcinoma cases (2, 3, 4).
- Trial name
- NCT06067594
- Testing
- Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement
- Where
- Argentina
- Volunteers
- 155 people
- Sponsor
- Austral University, Argentina
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Pheochromocytoma, Neuroblastoma
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
- Conditions
- Pheochromocytoma, Neuroblastoma, Paraganglioma, Medullary Thyroid Carcinoma
- Trial name
- NCT01373736
- Testing
- 123I-meta-iodobenzylguanidine
- Where
- Canada
- Sponsor
- Vancouver Coastal Health
Metastatic Medullary Thyroid Cancer
CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice
In this registry it is planned to include all Belgian patients diagnosed with aggressive and symptomatic unresectable locally advanced or metastatic Medullary Thyroid Cancer (MTC) who have been prescribed Caprelsa® (vandetanib).
- Trial name
- CaprelsaReg (NCT02109250)
- Testing
- Caprelsa
- Where
- 8 sites in Belgium
- Volunteers
- 10 people
- Sponsor
- Genzyme, a Sanofi Company